Campbell & Co Investment Adviser’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-10,023
Closed -$188K – 1167
2023
Q1
$188K Buy
+10,023
New +$165K 0.04% 740
2022
Q4
– Sell
-11,167
Closed -$214K – 1043
2022
Q3
$214K Sell
11,167
-2,878
-20% -$52.4K 0.05% 602
2022
Q2
$214K Sell
14,045
-3,705
-21% -$54.8K 0.06% 584
2022
Q1
$362K Sell
17,750
-2,850
-14% -$58K 0.1% 400
2021
Q4
$601K Buy
20,600
+6,500
+46% +$186K 0.21% 145
2021
Q3
$304K Sell
14,100
-7,900
-36% -$191K 0.1% 367
2021
Q2
$564K Buy
+22,000
New +$470K 0.23% 122

Other funds holding CDMO

Campbell & Co Investment Adviser's CDMO Position: Q2 2023 in Review

Campbell & Co Investment Adviser sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q2 2023, closing a stake of 10,023 shares — an estimated $188K sold.

Campbell & Co Investment Adviser first reported a position in CDMO in Q2 2021 and held it in 7 quarters. The position peaked at $601K in Q4 2021. 168 funds tracked by Wall St. Rank hold CDMO as of Q2 2023.

  • Campbell & Co Investment Adviser reported no remaining Avid Bioservices, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 10,023 Avid Bioservices, Inc. Common Stock shares in Q2 2023, an estimated $188K.
  • Campbell & Co Investment Adviser first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
  • Campbell & Co Investment Adviser's Avid Bioservices, Inc. Common Stock position peaked at $601K in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q2 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.